ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization
07. August 2024 17:30 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus® Sleep Technologies Announces Record Revenues
as it Emerges from Reorganization
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
30. Mai 2024 06:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
13. Mai 2024 09:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
09. Mai 2024 18:30 ET
|
ProSomnus Sleep Technologies, Inc.
Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
08. Mai 2024 20:53 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Sleep Technologies Takes Strategic Action to Position Company for Long-Term Success
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
22. Februar 2024 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
30. Januar 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29. Januar 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
08. Januar 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
21. Dezember 2023 08:30 ET
|
Apnimed, Inc.
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- Part of a two-study...